Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Binospan Composto
- Development stage
- Unknown
- Lead developer
- Cazi Química Farmacêutica
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Binospan Composto is a fixed-dose combination drug developed by Cazi Química Farmacêutica, containing the antispasmodic agent scopolamine butylbromide (also known as hyoscine butylbromide) and the non-opioid analgesic/antipyretic agent dipyrone (metamizole). It is approved in Brazil for the rapid relief of painful spasms and cramps associated with the gastrointestinal, biliary, and genitourinary tracts, including menstrual cramps (dysmenorrhea). Scopolamine butylbromide acts as a competitive antagonist at muscarinic acetylcholine receptors, particularly the M3 subtype, leading to smooth muscle relaxation in abdominal organs. Dipyrone acts primarily by inhibiting cyclooxygenase (COX) enzymes, thereby reducing prostaglandin synthesis and alleviating pain and fever. Together, these two active ingredients provide synergistic relief from spasmodic pain.
- Brand names
- Binospan Composto
- Other names
- butilbrometo de escopolamina + dipironabutilbrometo de escopolamina + dipirona monoidratadahyoscine butylbromide + dipyronehyoscine butylbromide + metamizolescopolamine butylbromide + dipyronescopolamine butylbromide + metamizolescopolamine butylbromide + metamizole sodium
02
Targets
M1 (Muscarinic acetylcholine receptor M1)CHRM2 (M2)CHRM3 (M3)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on Binospan Composto.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Binospan Composto.